Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
–News Direct– By David Willey, Benzinga Advancements in healthcare and medicine have helped contribute to the reduction in child mortality…